Pulmonary TB Clinical Trial
Official title:
Risk Factors and Biomarkers for Post-tuberculosis Lung Damage in a Chinese Cohort: Protocol for a Prospective Observational Study
This prospective study aims to determine the incidence of Post-tuberculosis lung damage (PTLD), examine trends in the changes in lung function, and investigate the impact of smoking and other factors on respiratory symptoms, lung function, and chest CT findings, which will aid in the development of prognostic and therapeutic strategies for PTLD.
Introduction: Post-tuberculosis lung damage (PTLD) refers to residual pulmonary impairment following the completion of tuberculosis (TB) treatment, characterized by persistent respiratory symptoms and abnormal pulmonary function. The risk factors and biomarkers for PTLD have been scarcely investigated. Additionally, it remains unclear whether and to what extent cigarette smoking affects PTLD in patients with TB. Methods and analysis: This prospective observational study will enroll 400 adult male ever-smoker or never-smoker patients aged 25-60 years, with newly confirmed active TB between 2022 and 2024 from the Department of Respiratory and Critical Care Medicine at Peking University Third Hospital and the Tuberculosis Department at Beijing Geriatric Hospital. Baseline data (age, smoking history, and smoking pack-years), clinical symptoms, lung functions, and chest CT (computed tomography) findings will be prospectively collected. Respiratory questionnaires, lung function measurements, and chest CT examinations will be completed during follow-up visits at 6 months after the initiation of TB treatment, immediately at the completion of TB treatment, and at 1 year, 2 years, and 3 years after the completion of TB treatment. Peripheral blood samples will be obtained at baseline to measure inflammatory mediators and cytokines in serum. The collected data will be analyzed to determine the incidence of and factors/biomarkers for PTLD after TB treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00933790 -
Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis
|
Phase 3 | |
| Completed |
NCT04645836 -
Impact of a Pharmacist-led Patient-centred Care Intervention Along With Text-Message Reminders, on the Management of Newly Diagnosed Tubercular Patients: a Protocol for a Randomized Controlled Trial'.
|
N/A | |
| Recruiting |
NCT06058299 -
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
|
Phase 2 | |
| Completed |
NCT03722472 -
Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults
|
Phase 1 | |
| Completed |
NCT03678688 -
A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis
|
Phase 1/Phase 2 | |
| Completed |
NCT00212550 -
Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb
|
N/A | |
| Recruiting |
NCT03025516 -
Performance Evaluation of TB Breath- and Cough-testing Platforms
|
N/A | |
| Completed |
NCT02961569 -
Comparison Between Two Strategies for the Diagnosis of TB
|
N/A | |
| Recruiting |
NCT04264221 -
Promoting Overall Care and Management Related to Tuberculosis Infection Through Pharmaceutical Care and Text Messaging
|
N/A | |
| Active, not recruiting |
NCT05221502 -
Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB
|
Phase 2 |